Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21172212 | 0.91 | NOD1 (0.50) | MEN1KMT2AFOLH1NOD1EPHX2 | |
| SCHEMBL29334247 | 0.84 | NOD1 (0.39) | FOLH1NOD1ALB | |
| SCHEMBL13197601 | 0.82 | MEN1 (0.59) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL16384378 | 0.82 | MEN1 (0.59) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL14217259 | 0.82 | MEN1 (0.59) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL16384384 | 0.82 | MEN1 (0.59) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL24135883 | 0.81 | C3AR1 (0.41) | FOLH1NOD1 | |
| SCHEMBL18116882 | 0.81 | MEN1 (0.57) | MEN1KMT2AFOLH1NOD1ALB | |
| SCHEMBL29330934 | 0.80 | CPB2 (0.39) | FOLH1NOD1 | |
| SCHEMBL15871316 | 0.79 | ALB (0.56) | MEN1KMT2AFOLH1NOD1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | MEN1 1278/4885KMT2A 1230/4885FOLH1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.